Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,782 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE. Nicholls SJ, et al. Among authors: anderson t. JAMA. 2016 Dec 13;316(22):2373-2384. doi: 10.1001/jama.2016.16951. JAMA. 2016. PMID: 27846344 Clinical Trial.
Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).
Puri R, Nissen SE, Somaratne R, Cho L, Kastelein JJ, Ballantyne CM, Koenig W, Anderson TJ, Yang J, Kassahun H, Wasserman SM, Scott R, Borgman M, Nicholls SJ. Puri R, et al. Am Heart J. 2016 Jun;176:83-92. doi: 10.1016/j.ahj.2016.01.019. Epub 2016 Feb 17. Am Heart J. 2016. PMID: 27264224 Clinical Trial.
Effect of Evolocumab on Coronary Plaque Composition.
Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJP, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Honda S, Shishikura D, Scherer DJ, Borgman M, Brennan DM, Wolski K, Nissen SE. Nicholls SJ, et al. Among authors: anderson t. J Am Coll Cardiol. 2018 Oct 23;72(17):2012-2021. doi: 10.1016/j.jacc.2018.06.078. J Am Coll Cardiol. 2018. PMID: 30336824 Free article. Clinical Trial.
C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV.
Nelson AJ, Puri R, Brennan DM, Anderson TJ, Cho L, Ballantyne CM, Kastelein JJ, Koenig W, Kassahun H, Somaratne RM, Wasserman SM, Nissen SE, Nicholls SJ. Nelson AJ, et al. Am J Prev Cardiol. 2020 Oct 6;3:100091. doi: 10.1016/j.ajpc.2020.100091. eCollection 2020 Sep. Am J Prev Cardiol. 2020. PMID: 34327467 Free PMC article.
Erratum to "C-Reactive Protein Levels and Plaque Regression with Evolocumab: Insights From GLAGOV" [American Journal of Preventive Cardiology 3C (2020) 100091].
Nelson AJ, Puri R, Brennan DM, Anderson TJ, Cho L, Ballantyne CM, Kastelein JJ, Koenig W, Kassahun H, Somaratne RM, Wasserman SM, Nissen SE, Nicholls SJ. Nelson AJ, et al. Am J Prev Cardiol. 2021 Feb 11;6:100153. doi: 10.1016/j.ajpc.2021.100153. eCollection 2021 Jun. Am J Prev Cardiol. 2021. PMID: 34374706 Free PMC article.
Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein-Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab.
Honda S, Puri R, Anderson T, Kastelein JJP, Brennan DM, Kassahun H, Somaratne R, Wasserman SM, Nissen SE, Nicholls SJ. Honda S, et al. Among authors: anderson t. JACC Cardiovasc Imaging. 2022 Apr;15(4):709-711. doi: 10.1016/j.jcmg.2021.11.014. Epub 2021 Dec 15. JACC Cardiovasc Imaging. 2022. PMID: 34922870 Free article. No abstract available.
Safety profile of extended-release niacin in the AIM-HIGH trial.
Anderson TJ, Boden WE, Desvigne-Nickens P, Fleg JL, Kashyap ML, McBride R, Probstfield JL; AIM-HIGH Investigators. Anderson TJ, et al. N Engl J Med. 2014 Jul 17;371(3):288-90. doi: 10.1056/NEJMc1311039. N Engl J Med. 2014. PMID: 25014706 Free PMC article. No abstract available.
Clinical factors associated with high-risk carotid plaque features as assessed by magnetic resonance imaging in patients with established vascular disease (from the AIM-HIGH Study).
Zhao XQ, Hatsukami TS, Hippe DS, Sun J, Balu N, Isquith DA, Crouse JR 3rd, Anderson T, Huston J 3rd, Polissar N, O'Brien K, Yuan C; AIM-HIGH Carotid MRI Sub-study Investigators. Zhao XQ, et al. Among authors: anderson t. Am J Cardiol. 2014 Nov 1;114(9):1412-9. doi: 10.1016/j.amjcard.2014.08.001. Epub 2014 Aug 13. Am J Cardiol. 2014. PMID: 25245415 Free PMC article.
Lp(a) (Lipoprotein(a)) Levels Predict Progression of Carotid Atherosclerosis in Subjects With Atherosclerotic Cardiovascular Disease on Intensive Lipid Therapy: An Analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) Carotid Magnetic Resonance Imaging Substudy-Brief Report.
Hippe DS, Phan BAP, Sun J, Isquith DA, O'Brien KD, Crouse JR, Anderson T, Huston J, Marcovina SM, Hatsukami TS, Yuan C, Zhao XQ. Hippe DS, et al. Among authors: anderson t. Arterioscler Thromb Vasc Biol. 2018 Mar;38(3):673-678. doi: 10.1161/ATVBAHA.117.310368. Epub 2018 Jan 4. Arterioscler Thromb Vasc Biol. 2018. PMID: 29301785 Free PMC article. Clinical Trial.
Effects of Extended-Release Niacin on Quartile Lp-PLA2 Levels and Clinical Outcomes in Statin-treated Patients with Established Cardiovascular Disease and Low Baseline Levels of HDL-Cholesterol: Post Hoc Analysis of the AIM HIGH Trial.
Lyubarova R, Albers JJ, Marcovina SM, Yao Y, McBride R, Topliceanu A, Anderson T, Fleg JL, Desvigne-Nickens P, Kashyap ML, McGovern ME, Boden WE. Lyubarova R, et al. Among authors: anderson t. J Cardiovasc Pharmacol Ther. 2019 Nov;24(6):534-541. doi: 10.1177/1074248419852955. Epub 2019 May 26. J Cardiovasc Pharmacol Ther. 2019. PMID: 31131629 Clinical Trial.
3,782 results